Detail akcie Livanova online

Business Summary: LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Financial Summary: BRIEF: For the six months ended 30 June 2025, LivaNova PLC revenues increased 9% to $669.4M. Net loss increased from $25.6M to $300.2M. Revenues reflect Cardiopulmonary segment increase of 14% to $375.6M, Neuromodulation segment increase of 5% to $290.6M, Europe segment increase of 20% to $126.5M, Rest of World segment increase of 10% to $185.3M, United States segment increase of 5% to $357.6M.